Каталог "Библиографии" | Списание
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
W.-J. Chng; V. Goranova-Marinova; et al.
Каталог "Библиографии" | Списание
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide- dexamethasone in relapsed multiple myeloma by previous treatment
Meletios A. Dimopoulos; V. Goranova-Marinova; et al.
Каталог "Библиографии" | Списание
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
P. Moreau; V. Goranova-Marinova; et al.
A 512
Каталог "Библиографии" | Списание
Serum levels of vitamin D in patients with multiple myeloma
Vasko Graklanov; Veselin Popov; Ralitsa Raycheva
Каталог "Библиографии" | Списание
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
S. Grosicki; V. S. Goranova-Marinova; et al.
Каталог "Библиографии" | Списание
Vitamin D levels in patients with non-Hodgkin lymphoma/diffuse large B-cell lymphoma, chronic lymphocytic leukemia and multiple myeloma
V. Graklanov; V. Popov
Каталог "Библиографии" | Списание
A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: Analysis of parameters that improve outcome
M. Beksac; V. Goranova-Marinova; et al.